U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 (Reuters) - Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.